Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

3SBio Acquires Rights to Novel Biologic Drug from SIMM

publication date: Oct 29, 2013
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
3SBio has acquired the China rights to a novel kidney disease treatment from the Shanghai Institute of Materia Medica. In animal models, the drug candidate slowed the progression of renal failure caused by an inherited disorder known as autosomal dominant polycystic kidney disease (ADPKD). 3SBio will ask the CFDA to approve a Phase I clinical trial in China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners